DRAFT: for discussion only. Requires Alveus medical, legal and regulatory review and IRB approval before use.

PRESERVEResearch Study Draft

See if you may qualify

Research study · Enrolling at 20 sites in 14 states (as of October 26, 2026)

Lost weight on a GLP-1? You may qualify for PRESERVE, a study testing an investigational drug for maintaining weight loss.

See if you may qualify How the study works
Who
Adults 18 to 75
Weight loss
10% or more on a GLP-1
Size
About 220 people
Where
20 sites in 14 states
Type
Phase 2, with placebo

About the study

PRESERVE is a Phase 2 study of ALV-100, an investigational drug (still being tested and not approved by the FDA). Phase 2 studies test different doses in a few hundred people to learn more about a drug’s safety and effects.

The study will compare how body weight changes over 24 weeks in people taking the study drug and people taking a placebo (a look-alike with no medicine in it). About 220 people will be split into four groups, each testing a different dose or schedule, and some people in each group will get the placebo. Safety is checked through week 36.

You’ll also fill out questionnaires about hunger, cravings and food noise (constant thoughts about food). Researchers will compare how these change with the study drug and with the placebo.

[Alveus to confirm: how the study drug is given and how often. Sources differ.]

Who can take part

You may be able to join if you:

  • are 18 to 75 years old
  • have lost at least 10% of your body weight on a GLP-1 or similar medicine taken for weight loss (the study calls these incretin-based medicines) [Alveus to confirm: which medicines count, such as Wegovy (semaglutide), Zepbound (tirzepatide) or compounded versions, and whether you must be taking it now]
  • have been on the same dose for at least 3 months in a row, with your weight holding steady for at least 3 months
  • have a BMI (body mass index) of 23 or higher [Alveus to confirm: one site’s listing says a BMI of 27 or higher and semaglutide only]
  • are tolerating your current medicine well, in the study doctor’s judgment
  • are willing to keep your usual eating and activity habits during the study

You can’t join if you:

  • have ever had type 1 or type 2 diabetes
  • have had weight-loss surgery or used a weight-loss device (such as a gastric balloon)
  • have a personal or family history of MTC or MEN 2 (a rare thyroid cancer and a related inherited condition)
  • have had cancer in the past 5 years
  • have taken a medicine in the past 3 months that can cause significant weight gain
  • have weight gain caused by certain hormone, brain or genetic conditions

The study team will go over the full list with you, and only they can confirm whether you qualify.

What taking part involves

  1. Answer a few questions to see if you may qualify.
  2. Talk with a study site. If you may qualify, a study site gets in touch to answer your questions. [Alveus to confirm: who contacts you and how]
  3. Screening visit. You go over the consent form (a document explaining the study, its risks and your rights), ask any questions you have and decide whether to join. If you sign, you’ll have health checks to confirm you qualify.
  4. Study visits. [Alveus to confirm: number of visits, how often, and how long each one is]
  5. End of the study. [Alveus to confirm: total time in the study and any follow-up. Results are tracked through week 36.]

Study drug or placebo

You’ll be randomly assigned to get the study drug or the placebo. Neither you nor your study doctor will know which one you’re getting, which keeps the results fair. [Alveus to confirm: your chance of getting the placebo]

Your current GLP-1 medicine

[Alveus to confirm: whether you stop your current GLP-1 medicine, when and how; what happens if your weight goes up; and whether you can restart it during or after the study.]

The study team will explain this before you decide, and it’s worth talking over with your own doctor too.

At study visits

Visits may include weight checks, blood pressure checks, blood tests for blood sugar and cholesterol, and questionnaires. [Alveus to confirm: full list of visit procedures, and whether you need to fast before some visits]

Your habits

You’ll be asked to keep your usual eating and activity habits. [Alveus to confirm: one site’s listing mentions diet and exercise counseling]

Costs and payment

You may be paid for your time at study visits. [Alveus to confirm: payment details, which costs are covered, and whether you need insurance]

Possible risks and benefits

Possible risks

  • The study drug may cause side effects, including some that aren’t known yet. [Alveus to confirm: known side effects to list from the consent form]
  • Your weight may go up during the study, whether you get the study drug or the placebo. [Alveus to confirm: wording, and what happens if it does]
  • If the study changes or stops your current GLP-1 medicine, your weight and appetite may change. [Alveus to confirm: whether this applies]
  • Blood draws can cause brief discomfort or bruising. [Alveus to confirm: wording]
  • Visits take time and may involve travel.

Possible benefits

  • At study visits, the study team will check your weight, blood pressure and blood work, though these checks don’t replace care from your own doctor. [Alveus to confirm: wording, and whether to list this as a benefit]
  • You’ll help researchers learn whether the study drug can help people keep weight off, which may help others in the future.

Before you decide, the study team will go over all known risks with you in the consent form. You can take your time, ask questions and talk with your own doctor.

Common questions

Do I have to stop my Wegovy or Zepbound, and can I go back on it later?

[Alveus to confirm: whether you stop your current GLP-1 medicine, when, whether it is tapered or stopped all at once, and whether and when you can restart it] The study team will explain exactly what happens with your current medicine before you agree to anything. After the study, your care is up to you and your own doctor.

What happens if I start gaining weight back?

The study team checks your weight at study visits, and you can leave the study at any time for any reason. [Alveus to confirm: what the study team does if your weight goes up, and what your options are]

What if I get the placebo?

The placebo looks like the study drug but has no medicine in it. Your weight may change whether you get the study drug or the placebo, and it’s checked the same way in both groups. Comparing the two groups is how researchers learn what the study drug does. [Alveus to confirm: your chance of getting the placebo]

Will it cost me anything?

[Alveus to confirm: whether study visits or the study drug cost you anything, whether you need insurance, and whether taking part affects your coverage or prescriptions] You can ask the study team about costs before you decide.

What are the possible side effects?

Because the study drug is still being tested, not all of its side effects are known, and checking its safety is one of the study’s goals. The consent form will list the known risks before you decide. [Alveus to confirm: known side effects to list]

Will the food noise (constant thoughts about food) come back?

How food noise changes during the study is one of the questions it’s designed to answer. You’ll fill out questionnaires about hunger, cravings and food noise, and researchers will compare the answers of people on the study drug with those on the placebo.

Is the study drug a shot or a pill, and how often would I take it?

[Alveus to confirm: how the study drug is given and how often. Sources differ.] The study is testing four combinations of dose and schedule.

Is there a study site near me, and how much time does it take?

There are 20 study sites in 14 states, listed in Study sites below. [Alveus to confirm: how many visits, how often, how long each one takes, and how long you’re in the study overall]

I’m on a low maintenance dose. Can I still join?

Possibly. What matters is that you’ve been on the same dose for at least 3 months in a row and your weight has held steady for at least 3 months. [Alveus to confirm: whether any dose counts]

Does compounded semaglutide or tirzepatide (made by a compounding pharmacy) count?

[Alveus to confirm: whether compounded versions count] The study team can tell you when they review your health history.

I have prediabetes, PCOS, sleep apnea or a thyroid condition. Can I join?

Possibly. The study team will review your health history, including conditions like PCOS (polycystic ovary syndrome), and decide. You can’t join if you’ve ever had type 1 or type 2 diabetes or have a personal or family history of medullary thyroid cancer (MTC) or MEN 2. You also can’t join if your weight gain is caused by certain hormone, brain or genetic conditions.

Do I have to change how I eat or exercise?

You’ll be asked to keep your usual eating and activity habits during the study. [Alveus to confirm: one site’s listing mentions diet and exercise counseling]

Will I find out whether I got the study drug or the placebo?

Not while the study is running, since neither you nor your study doctor will know. [Alveus to confirm: whether and when you’ll be told after the study ends]

Can I leave the study after I start?

Yes. You can leave at any time, for any reason, and it won’t affect your regular medical care.

Study sites

The study is running at 20 sites in 14 states (from ClinicalTrials.gov, checked October 26, 2026).

Alabama

  • Birmingham — University of Alabama - Birmingham

Arizona

  • Sun City — DM Clinical Research
  • Tempe — AMR Clinical

California

  • Oceanside — Profound Research

Florida

  • Bradenton — DM Clinical Research
  • Doral — DM Clinical Research
  • Orlando — Clinical Neuroscience Solutions

Georgia

  • Woodstock — North Georgia Clinical Research

Illinois

  • Champaign — Christie Clinic

Louisiana

  • Gretna — BRCR Global Louisiana

Michigan

  • Farmington Hills — Profound Research

New York

  • New York — ALSA Research-Manhattan

North Carolina

  • Wilmington — TMA Headlands

Oklahoma

  • Oklahoma City — Lynn Health Science Institute

Tennessee

  • Nashville — AMR Clinical

Texas

  • Irving — DM Clinical Research
  • San Antonio — DM Clinical Research - Dominion Family Healthcare
  • San Antonio — Tekton Research
  • Tomball — DM Clinical Research

Utah

  • South Jordan — AMR Clinical

See if you may qualify

Demo only: this form doesn’t send or save anything.

When it’s live, the form will take a few minutes. Your answers will be used only to check whether you may qualify and to connect you with a study site. [Alveus to confirm: who receives your answers, how long they are kept, and a link to the privacy notice]

Answering doesn’t sign you up. Taking part in the study is voluntary, and you can stop at any time, including after you join.

How old are you?
Which GLP-1 medicine are you taking now?
How long have you been on the same dose?
How much of your starting weight have you lost on it?
Has your weight stayed about the same for the last 3 months?
Is your BMI 23 or higher?

[Alveus to confirm: one site’s listing says a BMI of 27 or higher]

Have you ever been told you have type 1 or type 2 diabetes?
Have you had weight-loss surgery or used a weight-loss device?
Contact details (turned off in this demo)
Best time to reach you

Your choice and your privacy

  • Taking part is voluntary. You can say no, or leave at any time for any reason, and it won’t affect your regular medical care.
  • An independent ethics committee, called an institutional review board (IRB), reviews the study to help protect the people in it. [Alveus to confirm: IRB name and approval]
  • The consent form explains who can see your study records and how they’re protected. [Alveus to confirm: privacy notice]
  • This page doesn’t use cookies or tracking.